Advertisement
"With 13 abstracts covering eight clinical-stage compounds, the 2007AACR-NCI-EORTC meeting is an important opportunity to highlight the breadthand depth of our pipeline," said George A. Scangos, Ph.D., president and chiefexecutive officer of Exelixis. "Critical to our goal of building a world-classoncology franchise is the rapid advancement of the 14 compounds currently inthe clinic and the continued ability to advance additional compounds intodevelopment. We believe our strong presence at this meeting is evidence of ourproductivity. Three of the phase 1 compounds that will be discussed werepreclinical compounds at this time last year and we will present phase 2 datafrom trials that were initiated less than 18 months ago."
Advertisement
Exelixis will hold a briefing for investors and analysts on Wednesday,October 24, 2007, from 6:00-8:00 p.m. PDT / 9:00-11:00 p.m. EDT. During thebriefing, Exelixis management will review data for XL647, XL880 and XL184, inaddition to other Exelixis compounds. This webcast may be accessed in theEvent Calendar page under Investors on the Exelixis website athttp://www.exelixis.com. An archive of the webcast will be available until8:59 p.m. PST/11:59 p.m. EST on November 24, 2007. Access numbers for thereplay are 1-888-286-8010 (domestic) and 1-617-801-6888 (international). Thereplay passcode is 86296035.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated tothe discovery and development of novel small molecule therapeutics for thetreatment of cancer and other serious diseases. The company is leveraging itsfully integrated drug discovery platform to fuel the growth of its developmentpipeline, which is primarily focused on cancer. Currently, Exelixis' broadproduct pipeline includes investigational compounds in phase 2 and phase 1clinical development for cancer and renal disease. Exelixis has establishedstrategic corporate alliances with major pharmaceutical and biotechnologycompanies, including GSK, Bristol-Myers Squibb, Genentech, WyethPharmaceuticals and Daiichi-Sankyo. For more information, please visit thecompany's web site at http://www.exelixis.com.The full list of abstracts to be presented at the meeting follows: Phase 2 Clinical Abstracts -- A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) (Abstract #B249) -- A Phase II study of XL647 in Patients with Non-Small Cell Lung Cancer (NSCLC) Enriched for Presence of EGFR Mutations (Abstract #B124) Phase 1 Clinical Abstracts -- A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies (Abstract #A152) -- A phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL820 administered orally daily (QD) or twice daily (BID) to patients (pts) with solid malignancies (Abstract #B69) -- Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor (Abstract #C205) -- Biomarker development for XL765, a potent and selective oral
